Cytokinetics reported third quarter 2026 results, with total revenue of $47.6 million, up from $1.9 million a year earlier, driven by $44.5 million in MYQORZO net product revenue. The net loss narrowed to $190.1 million, or $1.37 per share, from $306.2 million, or $2.55 per share, a year earlier, and the company reaffirmed its full year 2026 GAAP combined R&D and SG&A expense guidance of $860 million to $890 million.
Total Q3 2026 revenue was $47.6 million, including $44.5 million of MYQORZO net product revenue and $3.1 million of collaboration revenue.
Net loss for Q3 2026 was $190.1 million, or $(1.37) per share, versus $306.2 million, or $(2.55) per share, in Q3 2025.
Cash, cash equivalents and investments were approximately $1.6 billion at September 30, 2026, compared with $1.7 billion at June 30, 2026.
Full year 2026 GAAP combined R&D and SG&A expense guidance of $860 million to $890 million was reaffirmed.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Cytokinetics's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$88.04M
+376.6%
$-6.54
—
-891.6%
FY2024
$18.47M
+145.3%
$-5.26
—
-3191.1%
FY2023
$7.53M
-92.0%
$-5.45
—
-6988.6%
FY2022
$94.59M
+34.3%
$-4.33
—
-411.2%
FY2021
$70.43M
+26.2%
$-2.80
—
-305.7%
Frequently asked questions
When is Cytokinetics's next earnings date?
Cytokinetics has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Cytokinetics earn last quarter?
For the quarter ended Sep 2026, Cytokinetics reported diluted EPS of $-1.37 on revenue of $47.56M (+2356.5%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.